ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

A Agilent Technologies

137.40
-1.29 (-0.93%)
Last Updated: 17:21:01
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agilent Technologies NYSE:A NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -1.29 -0.93% 137.40 139.885 136.71 139.23 299,972 17:21:01

Agilent Introduces Three New Microarrays for Prenatal and Postnatal Research

03/03/2020 1:00pm

Business Wire


Agilent Technologies (NYSE:A)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Agilent Technologies Charts.

Delivering up-to-date content for cytogenetic testing needs

Agilent Technologies Inc. (NYSE: A) today introduced three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal research.

The new Agilent GenetiSure Cyto microarrays include updated, clinically relevant content from respected databases. The probes on the Cyto microarrays provide high-resolution detection of copy number variations, and copy-neutral loss of heterozygosity associated with developmental delay, neuropsychiatric disorders, intellectual disability, congenital anomalies, or unexplained dysmorphic features in constitutional DNA samples.

“With the progression of next-generation sequencing, new gene-disease associations are being uncovered, and databases are evolving rapidly to include these discoveries,” said Kevin Meldrum, general manager of Agilent’s Genomics Solution Division. “Clinical researchers need to have a platform that will allow them to test for these relevant genetic aberrations.”

Meldrum noted that Agilent’s new arrays focus on clinically relevant regions with different specifications, depending on application (prenatal and postnatal research) down to exon-level resolution.

Dr. Svetlana Yatsenko, who directs the cytogenetics laboratory at the University of Pittsburgh Medical Center’s Magee-Women’s Hospital, in Pittsburgh, Pennsylvania, had this to say about the new microarrays:

“As a high-volume molecular cytogenetics laboratory, one of our key needs is having a microarray platform that contains the latest clinically-relevant content. Agilent GenetiSure Cyto microarrays meet this need. With a targeted design covering over 3600 genes and compatibility with a wide range of clinically relevant samples, we see it as a compelling solution for any laboratory trying to implement or upgrade their microarray testing needs.”

Agilent is a leading manufacturer of high-quality microarrays for copy number analysis and provides a complete workflow from sample preparation to interpretation.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Naomi Goumillout Agilent Technologies +1.781.266.2819 naomi.goumillout@agilent.com

1 Year Agilent Technologies Chart

1 Year Agilent Technologies Chart

1 Month Agilent Technologies Chart

1 Month Agilent Technologies Chart

Your Recent History

Delayed Upgrade Clock